FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to neurology, and can be used for treating primary sleep disorder. Patient is administered a therapeutically effective amount of (R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3,5]nonan-7-yl)ethanone or its pharmaceutically acceptable salt or a pharmaceutical composition containing therapeutically effective amount of (R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3,5]nonan-7-yl)ethanone or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier, diluent or excipient.
EFFECT: group of inventions provides earlier sleep start time and considerable increase of its duration, as well as reduction of appetite.
4 cl, 6 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3,5]NONANE DERIVATIVES AND USE THEREOF AS GHRELIN RECEPTOR ANTAGONISTS OR INVERSE AGONISTS | 2011 |
|
RU2524341C2 |
| ARYLPYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION | 1997 |
|
RU2189976C2 |
| SUBSTITUTED 2-ACYL-2-AMINOTHIAZOLES | 2005 |
|
RU2371438C2 |
| USE OF N-ARYLDIAZA SPIROCYCLIC COMPOUNDS FOR TREATING ADDICTIONS | 2005 |
|
RU2387647C9 |
| COMPOUNDS, ENHANCING GLUTAMATE RECEPTOR, AND THEIR APPLICATION IN MEDICINE | 2005 |
|
RU2403242C2 |
| MENIN-MLL INTERACTION INHIBITORS | 2017 |
|
RU2799820C2 |
| SULFONAMIDE COMPOUNDS AND SALTS THEREOF | 2009 |
|
RU2481329C2 |
| 3-BENZOFURANYLINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3, PREPARING AND USING THEM IN THERAPY | 2010 |
|
RU2542991C2 |
| SYNTHESIS AND USE OF TETRAHYDROPYROLLO[3,2-c]PYRIDIN-4-ONE DERIVATIVES TO TREAT OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | 2006 |
|
RU2415856C2 |
| RECEPTOR SUBTYPE-SELECTIVE AZABICYCLOALKANE DERIVATIVES | 2008 |
|
RU2417984C1 |
